Table 1 Initial characteristics and outcome of the prone positioned ARDS COVID-19 population (data are expressed as median (interquartile range, IQR) or number (%) as appropriate. After visual assumption of normality, Wilcoxon rank tests were applied for continuous variables. For categorical variables, Fisher’s exact or chi2 tests were applied as appropriate)
From: Usefulness and safety of a dedicated team to prone patients with severe ARDS due to COVID-19
Variables | n, total available | Total, n(%) or median (IQR) (n = 63) | n, available for ICU survivors (n = 46) * | ICU survivors, n(%) or median (IQR) * | n, available for ICU non-survivors (n = 16)* | ICU non-survivors, n(%) or median (IQR) * | p |
|---|---|---|---|---|---|---|---|
Demographic data | |||||||
Female ratio | 63 | 15 (24%) | 46 | 10 (22%) | 16 | 5 (31%) | 0.50 |
Age (years) | 63 | 64 (56–70) | 46 | 62 (54–69) | 16 | 67 (64–74) | 0.045 |
Weight (kg) | 61 | 89 (75–103) | 45 | 90 (80–103) | 15 | 89 (73–106) | 0.68 |
Body mass index (kg/m2) | 61 | 30 (25–36) | 45 | 30 (26–35) | 15 | 29 (25–46) | 0.87 |
SAPS II | 63 | 42 (31–57) | 46 | 37 (27–57) | 16 | 46 (42–59) | 0.030 |
Medical history | |||||||
Diabetes mellitus | 63 | 17 (27%) | 46 | 11 (24%) | 16 | 5 (31%) | 0.74 |
Hypertension | 63 | 30 (48%) | 46 | 19 (41%) | 16 | 10 (62%) | 0.14 |
Chronic respiratory disease | 63 | 16 (25%) | 46 | 13 (28%) | 16 | 3 (19%) | 0.53 |
Chronic immunosuppression† | 63 | 5 (8%) | 46 | 2 (4%) | 16 | 3 (19%) | 0.10 |
Chronic Cardiovascular disease | 63 | 16 (25%) | 46 | 12 (26%) | 16 | 3 (19%) | 0.74 |
Chronic kidney disease | 63 | 3 (5%) | 46 | 2 (4%) | 16 | 1 (6%) | 1.00 |
Respiratory parameters | |||||||
Static compliance (ml/cmH2O) before first prone positioning | 46 | 33 (23–42) | 35 | 35 (27–44) | 11 | 22 (18–36) | 0.036 |
PaO2/FIO2 ratio before first prone positioning | 63 | 92 (70–117) | 46 | 96 (70–120) | 16 | 86 (64–111) | 0.54 |
Number of prone positioning per patient | 63 | 3 (2–6) | 46 | 3 (2–6) | 16 | 4 (3–8) | 0.19 |
Events in ICU | |||||||
Vasopressors administered | 63 | 38 (60%) | 46 | 23 (50%) | 16 | 14 (88%) | 0.008 |
VV-ECMO | 63 | 14 (22%) | 46 | 11 (24%) | 16 | 3 (19%) | 1.00 |
Renal replacement therapy | 63 | 8 (13%) | 46 | 4 (9%) | 16 | 4 (25%) | 0.19 |
ICU length of stay (days) | 62 | 19 (14–31) | 46 | 20 (15–32) | 16 | 16 (12–28) | 0.24 |